These results supported the development of a phase I clinical trial of these CAR-iNK cells as monotherapy or in combination with daratumumab (anti-CD38 mAb) for treatment of patients with refractory/relapsed MM (NCT05182073). The gene discussed is CD38; the disease is Miyoshi myopathy.